ECM
BIOL

ETrade Capital Management’s Biolase, Inc. BIOL Stock Holding History

ETrade Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$10K Hold
14
– – ﹤0.01% 880
2020
Q2 		$17K Buy
+14
New +$15.9K ﹤0.01% 835

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ETrade Capital Management's BIOL Position: Q3 2020 in Review

ETrade Capital Management held its Biolase, Inc. (BIOL) position steady in Q3 2020 at 14 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

ETrade Capital Management first reported a position in BIOL in Q2 2020 and has held it in 2 quarters since. The position peaked at $17K in Q2 2020. 26 funds tracked by Wall St. Rank hold BIOL as of Q3 2020.

  • ETrade Capital Management held 14 shares of Biolase, Inc. worth $10K as of Q3 2020.
  • ETrade Capital Management left its Biolase, Inc. share count unchanged in Q3 2020.
  • Biolase, Inc. made up ﹤0.01% of ETrade Capital Management's portfolio in Q3 2020, its #880 holding.
  • ETrade Capital Management first reported a position in Biolase, Inc. in Q2 2020 and has held it in 2 quarters since.
  • ETrade Capital Management's Biolase, Inc. position peaked at $17K in Q2 2020.
  • 26 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.